FDA advisory committee thumbs up on Mesoblast's Ryoncil
Aug. 13, 2020 5:05 PM ETMesoblast Limited (MESO)By: Douglas W. House, SA News Editor1 Comment
• The FDA's Oncologic Drugs Advisory Committee voted 8-2 backing approval of Mesoblast Limited's (NASDAQ:MESO) Ryoncil (remestemcel-L) (ex-vivo culture-expanded adult human mesenchymal stromal cells suspension for intravenous infusion) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
• The positive vote surprised some observers considering the issues cited in the review team's briefing document.
• Trading, suspended this morning pending the outcome of the meeting, has yet to resume.
Congrats all especially The prof and board, what a moment for stem cell as well!
FDA advisory committee thumbs up on Mesoblast's RyoncilAug. 13,...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.030(2.73%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.21 | $1.05 | $28.73M | 25.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14264 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 24626 | 3 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
-0.030 ( 2.52 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.21 | $1.05 | 5190842 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| MSB (ASX) Chart |